Insulet Stock Forecast, Price & News

Insulet's stock was trading at $172.11 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, PODD shares have increased by 44.9% and is now trading at $249.39.
View which stocks have been most impacted by COVID-19.

19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Insulet in the last year. There are currently 1 sell rating, 10 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Insulet.

Insulet is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for Insulet.

Insulet will be holding an earnings conference call on Wednesday, November 4th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Insulet Co. (NASDAQ:PODD) announced its earnings results on Thursday, August, 6th. The medical instruments supplier reported $0.22 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.01) by $0.23. The medical instruments supplier earned $226.30 million during the quarter, compared to analysts' expectations of $212.41 million. Insulet had a return on equity of 10.96% and a net margin of 2.20%. The firm's quarterly revenue was up 27.8% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.02 earnings per share.
View Insulet's earnings history.

Insulet issued an update on its FY 2020 After-Hours earnings guidance on Thursday, August, 6th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $863.694-878.458 million, compared to the consensus revenue estimate of $849.76 million.

19 analysts have issued 1-year price objectives for Insulet's stock. Their forecasts range from $165.00 to $260.00. On average, they expect Insulet's stock price to reach $223.88 in the next twelve months. This suggests that the stock has a possible downside of 10.2%.
View analysts' price targets for Insulet.

Insulet saw a decline in short interest in the month of September. As of September 30th, there was short interest totaling 2,440,000 shares, a decline of 14.7% from the September 15th total of 2,860,000 shares. Based on an average daily volume of 409,100 shares, the days-to-cover ratio is presently 6.0 days.
View Insulet's Short Interest.

Some companies that are related to Insulet include Abbott Laboratories (ABT), Medtronic (MDT), Intuitive Surgical (ISRG), Stryker (SYK), Becton, Dickinson and (BDX), Boston Scientific (BSX), Edwards Lifesciences (EW), Baxter International (BAX), DexCom (DXCM), IDEXX Laboratories (IDXX), ResMed (RMD), Hologic (HOLX), Teleflex (TFX), Steris (STE) and Varian Medical Systems (VAR).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Insulet investors own include NVIDIA (NVDA), DexCom (DXCM), Netflix (NFLX), Alibaba Group (BABA), Tesla (TSLA), Square (SQ), The Walt Disney (DIS), salesforce.com (CRM), Roku (ROKU) and Trade Desk (TTD).

Insulet trades on the NASDAQ under the ticker symbol "PODD."

Insulet's stock is owned by many different retail and institutional investors. Top institutional shareholders include Standard Life Aberdeen plc (0.52%), Scout Investments Inc. (0.17%), Jag Capital Management LLC (0.14%), Assenagon Asset Management S.A. (0.07%), Envestnet Asset Management Inc. (0.07%) and State of Alaska Department of Revenue (0.04%). Company insiders that own Insulet stock include Aiman Abdel-Malek, Bret Christensen, Charles Alpuche, Corinne H Nevinny, David A Lemoine, David Colleran, Eric Benjamin, John A Fallon, Michael L Levitz, Michael P Spears, Sally Crawford and Shacey Petrovic.
View institutional ownership trends for Insulet.

PODD stock was sold by a variety of institutional investors in the last quarter, including Nisa Investment Advisors LLC, HWG Holdings LP, Jag Capital Management LLC, Tributary Capital Management LLC, and First Hawaiian Bank. Company insiders that have sold Insulet company stock in the last year include Bret Christensen, Charles Alpuche, Corinne H Nevinny, David A Lemoine, Eric Benjamin, John A Fallon, Michael P Spears, and Shacey Petrovic.
View insider buying and selling activity for Insulet.

PODD stock was bought by a variety of institutional investors in the last quarter, including Standard Life Aberdeen plc, Assenagon Asset Management S.A., State of Alaska Department of Revenue, Candriam Luxembourg S.C.A., Scout Investments Inc., Dearborn Partners LLC, Harel Insurance Investments & Financial Services Ltd., and IFM Investors Pty Ltd.
View insider buying and selling activity for Insulet.

Shares of PODD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of PODD stock can currently be purchased for approximately $249.39.

Insulet has a market capitalization of $16.37 billion and generates $738.20 million in revenue each year. The medical instruments supplier earns $11.60 million in net income (profit) each year or $0.19 on an earnings per share basis. Insulet employs 1,350 workers across the globe.

The official website for Insulet is www.insulet.com.

Insulet's mailing address is 100 NAGOG PARK, ACTON MA, 01720. The medical instruments supplier can be reached via phone at 978-600-7000 or via email at [email protected]